AU2020285718A1 - Fused heterocyclic derivatives - Google Patents

Fused heterocyclic derivatives Download PDF

Info

Publication number
AU2020285718A1
AU2020285718A1 AU2020285718A AU2020285718A AU2020285718A1 AU 2020285718 A1 AU2020285718 A1 AU 2020285718A1 AU 2020285718 A AU2020285718 A AU 2020285718A AU 2020285718 A AU2020285718 A AU 2020285718A AU 2020285718 A1 AU2020285718 A1 AU 2020285718A1
Authority
AU
Australia
Prior art keywords
compound
alkyl
mmol
formula
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020285718A
Other languages
English (en)
Inventor
Jan Martin Berke
Zhanling CHENG
Gang Deng
Lindsey Graham DERATT
Sandrine Céline Grosse
Lili Hu
Yimin Jiang
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Scott D. Kuduk
Morgan Charles R. LECOMTE
Carolina Martinez Lamenca
Serge Maria Aloysius Pieters
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Wim Gaston Verschueren
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020285718(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of AU2020285718A1 publication Critical patent/AU2020285718A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020285718A 2019-05-28 2020-05-27 Fused heterocyclic derivatives Abandoned AU2020285718A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933.0 2019-05-28
US62/853,533 2019-05-28
EP19176933 2019-05-28
CNPCT/CN2020/085720 2020-04-20
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
AU2020285718A1 true AU2020285718A1 (en) 2022-02-03

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020285718A Abandoned AU2020285718A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Country Status (19)

Country Link
EP (1) EP3976617B1 (https=)
JP (1) JP2022535734A (https=)
KR (1) KR20220012913A (https=)
CN (1) CN113906028A (https=)
AU (1) AU2020285718A1 (https=)
BR (1) BR112021022889A8 (https=)
CA (1) CA3138168A1 (https=)
CL (1) CL2021003155A1 (https=)
CO (1) CO2021016433A2 (https=)
CR (1) CR20210666A (https=)
DO (1) DOP2021000230A (https=)
IL (1) IL288322A (https=)
JO (1) JOP20210313A1 (https=)
MA (1) MA56043A (https=)
MX (1) MX2021014575A (https=)
PE (1) PE20220767A1 (https=)
PH (1) PH12021552974A1 (https=)
SG (1) SG11202113167QA (https=)
WO (1) WO2020243135A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744927A (zh) * 2020-12-02 2023-09-12 杨森科学爱尔兰无限公司 稠合杂环衍生物及其在治疗hbv感染中的用途
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
WO2022253255A1 (en) * 2021-06-02 2022-12-08 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
CN117715909A (zh) 2021-06-02 2024-03-15 杨森科学爱尔兰无限公司 稠合杂环衍生物
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
AU2017290755B2 (en) * 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6935434B2 (ja) * 2016-06-29 2021-09-15 ノヴィラ・セラピューティクス・インコーポレイテッド オキサジアゼピノン誘導体及びb型肝炎感染症の治療におけるその使用
SG11202111236UA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
WO2020243135A1 (en) 2020-12-03
EP3976617B1 (en) 2025-04-23
BR112021022889A2 (pt) 2022-01-04
PE20220767A1 (es) 2022-05-16
CR20210666A (es) 2022-03-11
PH12021552974A1 (en) 2022-07-11
DOP2021000230A (es) 2022-05-31
EP3976617A1 (en) 2022-04-06
CA3138168A1 (en) 2020-12-03
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
CL2021003155A1 (es) 2022-07-22
JP2022535734A (ja) 2022-08-10
MA56043A (fr) 2022-04-06
MX2021014575A (es) 2022-05-24
CN113906028A (zh) 2022-01-07
JOP20210313A1 (ar) 2021-11-25
SG11202113167QA (en) 2021-12-30
IL288322A (en) 2022-01-01
KR20220012913A (ko) 2022-02-04

Similar Documents

Publication Publication Date Title
AU2020285718A1 (en) Fused heterocyclic derivatives
KR20180022818A (ko) 환화 술파모일아릴아미드 유도체 및 b형 간염 치료용 약제로서의 이의 용도
TW202313008A (zh) 稠合雜環衍生物(一)
US20220348592A1 (en) Fused heterocyclic derivatives
WO2020243142A1 (en) Fused heterocyclic derivatives as antiviral agents
WO2020239864A1 (en) Fused heterocycle derivatives as capsid assembly modulators
WO2020243153A1 (en) Fused heterocyclic derivatives
WO2020239863A1 (en) Diazepinone derivatives as capsid assembly modulators
EA047929B1 (ru) Сочлененные гетероциклические производные
CN117715909A (zh) 稠合杂环衍生物
HK40066700A (zh) 稠合杂环衍生物
WO2022116998A1 (en) Fused heterocyclic derivatives as hbv inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GROSSE, SANDRINE CELINE; DERATT, LINDSEY GRAHAM; VANDYCK, KOEN; RABOISSON, PIERRE JEAN-MARIE BERNARD; PIETERS, SERGE MARIA ALOYSIUS; KESTELEYN, BART RUDOLF ROMANIE; VERSCHUEREN, WIM GASTON; BERKE, JAN MARTIN; LECOMTE, MORGAN CHARLES R.; MARTINEZ LAMENCA, CAROLINA; JONCKERS, TIM HUGO MARIA; DENG, GANG; JIANG, YIMIN; XU, YANPING; CHENG, ZHANLING; HU, LILI AND KUDUK, SCOTT D.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted